Status: Recruiting
SB17170 Phase 2 Trial in IPF Patients
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
Participants needed: 30
Trial details
Phase: Phase 2Age: 40+Biological sex: AllType: InterventionalSponsor: SPARK BiopharmaUpdated: Nov 19, 2025Locations: 5
Eligibility criteria
Adult male/female 40 years or older at the time of obtaining informed consent [+6]
When there is a primary disease showing UIP patterns (rheumatoid arthritis-relat... [+12]